A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic ...

Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...

Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel ...

Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

A study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

"We found that preexisting depression was associated with a 2.5-fold increase in mortality risk for patients with PCa, highlighting its role in exacerbating disease progression and worsening survival.

J&J receives CHMP positive opinion for Akeega to treat patients with metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations: Beerse, Belgium Monday, February 2, 2026, ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care, new data show.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.